Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (Tandem scFv) is designed to be expressed as a scFv from an anti-CD89 antibody variable domains fused with a scFv from an anti-EGFR antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.